AcelRx Pharmaceuticals (NASDAQ:ACRX) posted its quarterly earnings results on Friday. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.01), MarketWatch Earnings reports. The company had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $1.10 million.
ACRX traded up $0.65 during trading on Friday, reaching $4.80. 20,046,594 shares of the stock were exchanged, compared to its average volume of 5,918,827. The company has a market cap of $250.88 million, a price-to-earnings ratio of -4.36 and a beta of 2.03. AcelRx Pharmaceuticals has a 1 year low of $1.65 and a 1 year high of $5.05.
In other AcelRx Pharmaceuticals news, insider Lawrence G. Hamel sold 6,953 shares of the business’s stock in a transaction on Monday, September 24th. The stock was sold at an average price of $4.50, for a total transaction of $31,288.50. Following the sale, the insider now directly owns 24,371 shares in the company, valued at $109,669.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Badri N. Dasu sold 28,351 shares of the business’s stock in a transaction on Monday, October 15th. The stock was sold at an average price of $5.00, for a total value of $141,755.00. Following the sale, the insider now owns 54,061 shares in the company, valued at $270,305. The disclosure for this sale can be found here. Over the last quarter, insiders have acquired 57,300 shares of company stock worth $159,552. 25.50% of the stock is owned by company insiders.
A number of research firms recently weighed in on ACRX. LADENBURG THALM/SH SH set a $10.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Friday. ValuEngine upgraded AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday. Cantor Fitzgerald set a $8.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Friday. B. Riley began coverage on AcelRx Pharmaceuticals in a research note on Tuesday, October 23rd. They issued a “buy” rating and a $9.00 price target on the stock. Finally, Royal Bank of Canada set a $7.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. AcelRx Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $7.64.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
See Also: Fiduciary
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.